To assess the effectiveness of Systane COMPLETE in improving meibomian gland score and in reducing symptoms of ocular dryness.

Purpose: To assess the effectiveness of Systane COMPLETE in reducing symptoms of ocular dryness and improving Meibomian Gland (MG) Score in subjects with mild to moderate dry eye disease (DED). Methods: A prospective, interventional, single-center, single-arm study was conducted including cases of mild to moderate DED. Participants were prescribed a topical lipid-based combination of propylene glycol (PG) and hydroxypropyl guar (HPG) (Systane® COMPLETE), administered four times daily for 30 days. Dry eye assessment parameters, Meibo score, and Ocular Surface Disease Index (OSDI) questionnaire responses were obtained before and after treatment. Results: A total of 105 cases with mild to moderate DED were included in the study. Statistically significant improvements were observed in tear breakup time (TBUT) (p<0.0001), Schirmer's test (p<0.0001), lipid layer thickness (LLT) (p<0.0001), tear meniscus height (TMH) (p=0.0002), non-invasive breakup time (NIBUT) (p<0.0001), OSDI (p<0.0001), upper lid meibomian gland score (p=0.02), corneal staining score (p<0.0001). The change in Meibo score was not statistically significant (p=0.19). Conclusion: A lipid-based nanoemulsion of PG-HPG helps in improving the objective parameters and symptoms of DED. Additionally, it may support improved meibomian gland function.